Lilly teams up with CureVac in $1.8 billion cancer vaccine partnership
October 19, 2017Research and Development, Sales and Marketing Cancer, CureVac, Eli Lilly, Vaccine
Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to …
Vir Biotech blasts out of the blocks, with $500m in bank
October 19, 2017Medical Communications, Sales and Marketing Vir Biotechnology, biotech, drugs, pharma, pharmaceutical
All has been quiet since former Biogen CEO, George Scangos, departed the company and then set up Vir Biotechnology in …
Novo’s diabetes treatment semaglutide gets unanimous FDA backing
October 19, 2017Sales and Marketing Novo Nordisk, diabetes, semaglutide
Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one …
Gilead gets FDA nod for revolutionary blood cancer treatment
October 19, 2017Sales and Marketing CAR-T, Gilead, Yescarta, biotech, drugs, pharma, pharmaceutical
Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s …
First-ever study in the personalised treatment of rare cancers brings promising results
October 18, 2017Research and Development Cancer, Cancer Research UK, personalised medicine, pharma, rare cancer
The first-ever trial to treat patients for rare cancers in a personalised manner based on the characteristics of their individual …
Breakthrough AI able to identify 97% of breast cancer risk
October 18, 2017Research and Development MIT, biotech, breast cancer, drugs, pharma, pharmaceutical
Scientists at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a machine learning AI system that is able diagnose …
Novartis sheds generics plant and 450 jobs amid pricing pressure
October 18, 2017Manufacturing and Production, Research and Development Novartis, US, closure, generics, manufacturing, pharma
Novartis has announced its intention to shut down its US generics manufacturing plant in Broomfield, Colorado, a move that will …
New studies point to cracks forming in NHS services
October 18, 2017Medical Communications, Research and Development NHS, biotech, drugs, pharma, pharmaceutical
Two studies published separately by the BBC and the Care Quality Commission (CQC) point to growing problems across NHS services …
J&J’s third quarter: The good and the bad
October 18, 2017Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be …
Allergan’s patent shield – The (Native) American dream?
October 17, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, biotech, drugs, pharma, pharmaceutical
In an unprecedented move, leading global pharmaceutical company Allergan appears to have handed its Orange Book-listed US patents covering …
AstraZeneca lung cancer drug proves able to shrink EGFR mutation-positive tumours
October 17, 2017Manufacturing and Production, Research and Development AstraZeneca, Cancer, Chi-Med, lung cancer, pharma, savolitinib
AstraZeneca and its partner Hutchison China MedTech, also known as Chi-Med, have announced positive data for savolitinib in combination with …
Peanut allergies? There’s a clinical trial looking to fix that
October 17, 2017Manufacturing and Production, Research and Development Aimmune, Regeneron, Sanofi, biotech, drugs, peanuts, pharma, pharmaceutical
Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …
EMA responds to criticism of its cancer drug approvals
October 17, 2017Manufacturing and Production, Medical Communications Cancer, EMA, biotech, drugs, oncology, pharma, pharmaceutical
The EMA received a broadside just less than two week ago from a group of researchers that had studied data …
Sanofi plans summit to tackle diabetes in 5 million Nigerian citizens
October 17, 2017Manufacturing and Production, Medical Communications Nigeria, Sanofi, WHO, diabetes, pharma
Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million …
Trump suggests he will declare opioid national emergency next week
October 17, 2017Manufacturing and Production, Sales and Marketing President trump, Trump, biotech, drugs, pharma, pharmaceutical
Back in August, President Trump had suggested that the opioid epidemic that is ravaging the US would be declared a …
Asking the right questions: Measuring the impact of pharmacovigilance
October 16, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drug safety, pharma, pharmacovigilance
Are our pharmacovigilance measures as effective as we think? And why is it important to answer that question, especially now? …
Simplify your regulatory processes
October 16, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, veeva
It’s always crunch time for regulatory operations. Whether you’re managing plans and documents for an upcoming IND or producing routine product variations, …
Trials reveal two strong vaccine candidates for Ebola
October 16, 2017Research and Development, Sales and Marketing Ebola, biotech, drugs, pharma, pharmaceutical
Two clinical-stage vaccine candidates for Ebola have produced stunning results, not least because an unexpected protection emerged. The two therapies …
FDA expands Janssen’s Stelara to cover adolescent psoriasis patients
October 16, 2017Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis
Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …
AstraZeneca admits cancer data for acquired drug was fabricated
October 16, 2017Research and Development, Sales and Marketing Acerta, AstraZeneca, acalabrutinib
AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
